Objective Capital Global Mining Investment Conference series in:

London 29-30 Sep, 09
Abu Dhabi 3-4 Nov, 09
Shanghai April, 2010

Objective Capital partners Sach's 9th Biotech in Europe Investor Forum 2009, Zurich
Sept, 2009

Objective Capital sponsor's City Zone CEO Clinic on 'How to engage UK and overseas small cap investors in your business'
21 May, 2009

Objective Capital sponsor's City Zone Enterprise Bar event on 'Convincing Investors: the power of research'
31 March, 2009

Objective Capital to be a platinum sponsor of 2nd Annual Global Capital Forum 2008, London
Oct, 2008

Objective Capital to host New York presentation on 'The future of Biofuels - Jatropha and Algae?'
Sept, 2008

Objective Capital partners Sach's 8th Biotech in Europe Investor Forum 2008, Zurich
Sept, 2008

Objective Capital hosts New York presentation on mining in 'Albania - revisiting old frontiers'
July, 2008

Join us at the Objective Capital Small Cap Forum in London on 20 June 2008
June, 2008

Meet Objective Capital at the 2008 World Resource Show, Vancouver
June, 2008

Join us at Objective Capital's series of region workshops on the role of research for AIM companies

London 6 June, 2008
Bristol 13 June, 2008
Leeds 20 June, 2008

Join us at the Objective Capital Small Cap Forum in London on 14 March 2008
March, 2008

Objective Capital, gold sponsor to the PDAC Convention and Investor Exhibition 2008, Toronto
March, 2008

Objective Capital to sponsor North of 60, the leading conference for northern resource projects
Feb, 2008

Meet Objective Capital at the 2008 Vancouver Gold Show, Vancouver
Jan, 2008

Objective Capital invited to lead delegation of junior mining companies to MENA-EX 2008, Saudi Arabia
Dec, 2007

Objective Capital to be gold sponsor of Mines & Money 2007, London
Nov, 2007

Meet Objective Capital at the 2007 San Francisco Hard Asset Mining Show
Oct, 2007

Objective Capital to present at the London Stock Exchange's 4th annual FinLab for CIS companies
Sept, 2007

Objective Capital to be a platinum sponsor of Global Capital Forum 2007, London
August, 2007

Objective Capital sponsors Nunavut 2007, the leading conference for Nunavut based resource companies
Feb, 2007

Contact us for more details
 

Despite the global recession, Colt Resources is continuing its exploration of the Penedono gold project and the Armamar Merda tungsten project, which are both in northern Portugal. The Armamar Meda concession, which surrounds the Penedono property, is showing good potential for tungsten. Despite the tough economic climate for resource companies, Colt continues to examine new opportunities, and the company has added four new prospects in the Gaspesie region of Quebec.

Our revised model yields a core valuation of C$0.28 per share, slightly higher than the C$0.26 value contained in our June 2008 initiation note. Our revised estimate remains subject to substantial risk given the early stage of exploration and uncertain economic conditions, but are accompanied by significant upside potential with more optimistic expectations of exploration success and continued development.
Read More | Previous Reports

NioGold Mining Corp (NOX.V) - valuation robust despite recession and sector meltdown
Mar 10, 2009
NioGold is pressing ahead with exploration of its gold projects in the famous Val d’Or mining district of Quebec. The company also holds a polymetallic project at an earlier stage of exploration, also in Quebec, and it has added a new prospect since our initiation note of June 2008. With its strong focus on gold in a historic and accessible region of Canada, our valuation of NioGold remains robust at C$0.23 per share, despite the global recession and resource sector meltdown.
Read More | Previous Reports

Bridge BioResearch (private) - with some glimmer of efficacy, and safety already in evidence, clinical validation could offer lucrative returns
Dec 03, 2008
Bridge BioResearch plc is focused on innovative emerging drugs for the treatment of metabolic/lifestyle diseases. Its two lead candidates, currently advancing into clinical trials, are innovative drug concepts in the related fields of diabetes and obesity. With some glimmer of efficacy, and safety already in evidence, upcoming clinical validation could put the company on the road to lucrative upfront, milestone and royalty payments.
Read More | Previous Reports

e-Therapeutics (ETX.L) - ‘success-predictive’ drug discovery may be the key to new treatment horizons
Nov 18, 2008
e-Therapeutics’ brand of ‘success-predictive’ drug discovery, based on bioinformatics and the analysis of complex biological systems, holds the potential, if clinically validated, to open up entirely new horizons in the treatment of complex, intractable or poorly treated diseases.
Read More | Previous Reports

Great Western Minerals (GWG.V) - pressing ahead with mine-to-market strategy
Nov 07, 2008
Great Western Minerals is pressing ahead with exploration at its Hoidas Lake rare earth elements deposit in northern Saskatchewan. It is also drilling on a second rare earth project, in Utah USA. The company recently acquired Less Common Metals and it continues development of Great Western Technologies Inc. Both companies focus on development and marketing of value-added rare earth alloys for the aerospace, automotive and high-technology sectors.
Read More | Previous Reports

Sofame Technologies (SDW.V) - confirmation of new orders
May 14, 2009 | Previous  

Sofame Technologies (SDW.V) - management changes and strengthing of sales
May 07, 2009 | Previous  

Sofame Technologies (SDW.V) - company plans C$5m fund raising
Apr 30, 2009 | Previous  

Sofame Technologies (SDW.V) - cancellation of acquisition a blessing in disguise
Apr 24, 2009 | Previous  

Colt Resources (COLT.CNQ) - Armamar Meda concession showing good potential
Mar 13, 2009 | Previous  

NioGold Mining Corp (NOX.V) - valuation robust despite recession and sector meltdown
Mar 10, 2009 | Previous  

NioGold Mining Corp (NOX.V) - continues to produce intriguing gold assays
Feb 06, 2009 | Previous  

e-Therapeutics (ETX.L) - results of its pilot Phase IIa in Major Depressive Disorder
Jan 14, 2009 | Previous  

York Pharma (YRK.L) - forced to return Flammazine/Flammacerium to Solvay
Jan 14, 2009 | Previous  

Sofame Technologies (SDW.V) - recent news flow indicates the company continues to make progress
Dec 17, 2008 | Previous  

NioGold Mining Corp (NOX.V) - assays continue to demonstrate potential
Dec 10, 2008 | Previous  

Bridge BioResearch (private) - with some glimmer of efficacy, and safety already in evidence, clinical validation could offer lucrative returns
Dec 03, 2008 | Previous  

e-Therapeutics (ETX.L) - ‘success-predictive’ drug discovery may be the key to new treatment horizons
Nov 18, 2008 | Previous  

NioGold Mining Corp (NOX.V) - more encouraging assays
Nov 12, 2008 | Previous  

LiDCO (LID.L) - half year results show early signs of being on track
Oct 30, 2008 | Previous Reports

Sofame Technologies (SDW.V) - reducing costs, curbing fuel usage and carbon reduction is a powerful combination
Oct 29, 2008 | Previous Reports

York Pharma (YRK.L) - acquisition of the Solvay product line is a company-transforming event
Oct 17, 2008 | Previous Reports

Albania - revisiting old frontiers
Oct 08, 2008 | Previous Reports

Balkan Resources (private) - exploration junior with sharp focus on Albanian
Oct 08, 2008 | Previous Reports

JAB Resources (private) - defining a chromite project in Albania
Oct 08, 2008 | Previous Reports

Balkan Resources (private) - exploration junior with sharp focus on Albanian
Oct 08, 2008 | Previous Reports

JAB Resources (private) - defining a chromite project in Albania
Oct 08, 2008 | Previous Reports

SilverCrest Mining (SVL.V) - revised valuation of C$1.32 per share
Sep 22, 2008 | Previous Reports

London Capital (LCG.L) - recent results confirm our forecasts
Aug 12, 2008 | Previous Reports

Tirex Resources (TXX.V) - continuing the first modern exploration programme in Albania
Aug 08, 2008 | Previous Reports

Albania - revisting old frontiers
October, 2008

The rise of independent research (IR Magazine)
March, 2006

Presentation to 2005 AIM Conference
Sept 26, 2005

The Role of Sponsored Research
June 22, 2005

Objective's Corporate Brochure
July 01, 2004